Value for money of medicine sampling and quality testing: evidence from Indonesia
Authors:
- Sara Valente de AlmeidaSASara Valente de Almeida
- Katharina HauckKHKatharina Hauck
- Sarah NjengaSNSarah Njenga
- Yunita NugrahaniYNYunita Nugrahani
- Ayu RahmawatiARAyu Rahmawati
- Rahmi MawaddatiRMRahmi Mawaddati
- Stanley SaputraSSStanley Saputra
- Amalia HasnidaAHAmalia Hasnida
- Elizabeth PisaniEPElizabeth Pisani
- Yusi AnggrianiYAYusi Anggriani
- Adrian GheorgheAGAdrian Gheorghe
Open Access
- 23 September 2024
- journal article
- research article
- Published by BMJ in BMJ Global Health
- Vol. 9 (9) , e015402
Abstract
Background Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM? Methods Between February and October 2022, Systematic Tracking of At Risk Medicines (STARmeds) collected and analysed for quality 1274 samples of 5 medicines from physical and online retail outlets in 7 Indonesian districts. We collated data on the resources consumed by STARmeds, related to all stages of medicines sampling and quality testing including design, fieldwork and laboratory analysis. We used activity-based costing principles to calculate the financial and economic cost of medicine quality surveillance from the perspective of a hypothetical medicines’ regulator. We calculated the cost per day and per week of fieldwork, per sample collected and per substandard sample. We used bootstrapping to capture uncertainty in the number of samples collected, by seller location type (urban, rural and online). Results The total cost of sampling and testing medicines from the market was US$712 964 (current 2022 values). Laboratory costs represented the largest share (70%), followed by other direct costs (12%) and indirect costs (7%). On average, it costs STARmeds US$479 (95% CI US$462 to US$516) to collect one medicine sample and US$5990 (95% CI US$5601 to US$6258) to identify one substandard sample. Conclusion Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care remits.Keywords
Funding Information
- National Institute for Health and Care Research (NIHR131145)
This publication has 16 references indexed in Scilit:
- Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: A Kenya case studyPLOS ONE, 2023
- Cost-analysis of COVID-19 sample collection, diagnosis, and contact tracing in low resource setting: The case of Addis Ababa, EthiopiaPLOS ONE, 2022
- Substandard and falsified medical products: bibliometric analysis and mapping of scientific researchGlobalization and Health, 2021
- Costing electronic private sector malaria surveillance in the Greater Mekong SubregionMalaria Journal, 2021
- THE DETERRENT EFFECT OF SURVEILLANCE CAMERAS ON CRIMEJournal of Policy Analysis and Management, 2021
- Determining the Operating Costs of a Medical Surveillance Program for Copper Miners Exposed to High Altitude–Induced Chronic Intermittent Hypoxia in Chile Using a Combination of Microcosting and Time-Driven Activity-Based CostingValue in Health Regional Issues, 2019
- Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and RomaniaWellcome Open Research, 2019
- Does the Police-Monitored CCTV Scheme Really Matter on Crime Reduction? A Quasi-Experimental Test in Taiwan’s Taipei CityInternational Journal of Offender Therapy and Comparative Criminology, 2018
- Police-monitored CCTV cameras in Newark, NJ: A quasi-experimental test of crime deterrenceJournal of Experimental Criminology, 2011
- Guidelines for Field Surveys of the Quality of Medicines: A ProposalPLOS Medicine, 2009